



PEER-REVIEW REPORT

Name of journal: *World Journal of Gastrointestinal Oncology*

Manuscript NO: 69305

Title: Consensus molecular subtypes of colorectal cancer in clinical practice: A translational approach

Reviewer's code: 05387405

Position: Peer Reviewer

Academic degree: MSc, PhD

Professional title: Research Scientist

Reviewer's Country/Territory: Hungary

Author's Country/Territory: Chile

Manuscript submission date: 2021-06-24

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-07-18 07:08

Reviewer performed review: 2021-07-22 08:14

Review time: 4 Days and 1 Hour

Scientific quality	<input checked="" type="checkbox"/> Grade A: Excellent [] Grade B: Very good [] Grade C: Good [] Grade D: Fair [] Grade E: Do not publish
Language quality	<input checked="" type="checkbox"/> Grade A: Priority publishing [] Grade B: Minor language polishing [] Grade C: A great deal of language polishing [] Grade D: Rejection
Conclusion	[] Accept (High priority) [] Accept (General priority) <input checked="" type="checkbox"/> Minor revision [] Major revision [] Rejection
Re-review	[] Yes <input checked="" type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous [] Onymous Conflicts-of-Interest: [] Yes <input checked="" type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

SPECIFIC COMMENTS TO AUTHORS

Authors of the article presented a minireview about consensus molecular subtypes (CMS) in colorectal cancer (CRC). The paper fits the scope of the journal and it is well written and easy to follow. The following minor issues should be resolved: 1. Abstract: "for metastasis CRC" -> metastatic 2. Abstract: "oncology routine practice" -> routine oncology care (?) 3. Introduction: GLOBOCAN 2020 data just came out recently (DOI 10.3322/caac.21660), I recommend to update the first citation with that. 4. "It is associated with infiltration and immune activation" -> It is associated with lymphocyte infiltration and immune activation 5. TGF-B -> TGF- β (?) 6. "and better OS in CM2 (29.0 months), whereas CM3 (18.6 months) and" -> CMS2 and CMS3 7. "...fusion protein with successful results in murine CRC models. This treatment has demonstrated an anti-tumor response by TGF β and PD-L1 immunosuppressive pathways with successful results in murine CRC models[46,47]." Do not replicate the same information. After resolving these small issues, I recommend publishing the article.